| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Hikaru Samejima CEO | TWSE Exchange | TW0004543004 ISIN |
| JP Country | 30,207 Employees | 29 Sep 2026 Last Dividend | 28 Mar 2024 Last Split | - IPO Date |
Terumo Corporation, headquartered in Tokyo, Japan, is a globally recognized company in the medical product and equipment manufacturing sector. Its operations span across various continents including Japan, Europe, China, the United States, and other parts of Asia. The company's history dates back to 1921, initially founded as Sekisen Ken-onki Corporation before adopting its current name in October 1974. Terumo's business activities are organized into three main segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company, each focusing on distinct medical technologies and solutions aimed at improving patient care and medical outcomes.
Offers a wide range of products for cardiology and endovascular therapies, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, and stents. Their portfolio extends to devices for treating cerebral aneurysm (coils, stents, and intrasaccular devices), embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. They also produce oxygenators, cardio-pulmonary bypass systems, and artificial vascular and stent grafts.
Provides products aimed at general medical care such as syringes, infusion and syringe pumps, infusion lines, and IV solutions. Their offerings include peritoneal dialysis fluids, pain management, and nutritious food products. Additionally, they provide blood glucose monitoring systems, disposable needles for pen injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Terumo also engages in contract manufacturing of prefilled syringes and needles for pharmaceutical packaging.
Specializes in products for blood management and cellular technologies, including blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, and centrifugal apheresis systems. They also offer solutions for cell expansion, supporting advanced therapies and research in the life sciences sector.